Monsanto Patent Suits Challenge mRNA Vaccine Foundations

Industry Insights from Next Move Strategy Consulting

Bayer's Monsanto Sues Pfizer, BioNTech, Moderna Over mRNA

A major legal confrontation has erupted in the pharmaceuticals sector as Bayer's Monsanto unit files patent infringement lawsuits against the dominant developers in the COVID-19 vaccine market: Pfizer, BioNTech, and Moderna. The lawsuits, filed in Delaware federal court, allege these companies improperly utilized foundational mRNA stabilization technology originally pioneered by Monsanto for agricultural applications in the 1980s.

A Legal Challenge Rooted in Agricultural Innovation

The complaints center on intellectual property developed decades ago, asserting that the scientific approach used to stabilize messenger RNA in crops forms the technological bedrock for today's groundbreaking vaccines. According to the filing, Monsanto scientists in the 1980s pioneered methods to reduce mRNA instability to create more pest-resistant crops—technology Bayer claims has been directly copied to stabilize the genetic material in COVID-19 vaccines.

Bayer has taken similar legal action in a New Jersey federal court against Johnson & Johnson, arguing that a DNA-based process used in manufacturing its now-discontinued shot infringes on Monsanto's patent. The company clarified it is not seeking to halt vaccine production but is pursuing unspecified monetary damages for the alleged infringement.

Industry Response and Broader Patent Landscape

Moderna has acknowledged the lawsuit, stating it will defend itself against the claims. Spokespeople for Pfizer, BioNTech, and Johnson & Johnson had not immediately responded to requests for comment. This litigation adds complexity to an already intricate web of patent disputes surrounding COVID-19 vaccines, including an ongoing case Moderna filed against Pfizer and BioNTech in 2022.

Despite the blockbuster status of the vaccines, with Pfizer/BioNTech's Comirnaty generating over $3.3 billion in 2024 revenue and Moderna's Spikevax earning $3.2 billion, these figures represent a significant decline from peak pandemic sales. Johnson & Johnson ceased selling its COVID-19 vaccine in the United States in 2023.

Next Move Strategy Consulting – Market Analysis

This legal development represents a significant inflection point for the biotechnology and pharmaceutical sectors. The outcome of these lawsuits could establish critical precedents for intellectual property rights surrounding foundational platform technologies, potentially influencing investment patterns, research and development priorities, and partnership models across the industry. A ruling favoring Monsanto may compel vaccine manufacturers and other biotech firms to reevaluate their freedom-to-operate analyses and licensing strategies, particularly for technologies with cross-sector applications. Conversely, a defense victory would reinforce the current innovation framework. Regardless of outcome, this litigation highlights the growing strategic value of historical patent portfolios and may accelerate industry consolidation as companies seek to bolster their intellectual property defenses in an increasingly competitive landscape.

Redefining Innovation Boundaries

As the pharmaceutical industry continues to evolve beyond the pandemic era, Monsanto's lawsuits underscore the complex interplay between historical research and contemporary medical breakthroughs. These cases will test the boundaries of patent protection across different application domains and could reshape how intellectual property rights are managed in an era of convergent technologies. The litigation's progression will be closely monitored for its potential to influence not only significant financial settlements but also the fundamental frameworks governing biotechnological innovation.

Source: ABC Net AU

Prepared by: Next Move Strategy Consulting